Zevenbergen Capital Investments LLC raised its position in DexCom, Inc. (NASDAQ:DXCM) by 22.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 821,660 shares of the medical device company’s stock after acquiring an additional 149,510 shares during the quarter. DexCom makes up about 2.6% of Zevenbergen Capital Investments LLC’s investment portfolio, making the stock its 17th largest holding. Zevenbergen Capital Investments LLC owned 0.95% of DexCom worth $60,104,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in DXCM. Capstone Asset Management Co. acquired a new stake in DexCom in the first quarter valued at $213,000. Great West Life Assurance Co. Can lifted its stake in DexCom by 6.4% in the first quarter. Great West Life Assurance Co. Can now owns 27,413 shares of the medical device company’s stock valued at $2,320,000 after acquiring an additional 1,647 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in DexCom by 4.1% in the first quarter. Advisors Asset Management Inc. now owns 8,179 shares of the medical device company’s stock valued at $693,000 after acquiring an additional 322 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in DexCom by 238.8% in the first quarter. BNP Paribas Arbitrage SA now owns 4,476 shares of the medical device company’s stock valued at $379,000 after acquiring an additional 3,155 shares during the last quarter. Finally, World Asset Management Inc acquired a new stake in DexCom in the first quarter valued at $317,000.

A number of brokerages have commented on DXCM. Piper Jaffray Companies reiterated a “buy” rating and issued a $78.00 price target on shares of DexCom in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $92.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. BidaskClub cut shares of DexCom from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. BMO Capital Markets restated an “outperform” rating and set a $90.00 target price (down previously from $105.00) on shares of DexCom in a research note on Tuesday, August 8th. Finally, Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $86.87.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/22/dexcom-inc-dxcm-holdings-increased-by-zevenbergen-capital-investments-llc.html.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $71.86, for a total transaction of $431,160.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,773 shares of company stock worth $1,767,873. Insiders own 1.70% of the company’s stock.

Shares of DexCom, Inc. (DXCM) traded up 0.7481% during mid-day trading on Friday, reaching $70.0199. 234,854 shares of the company’s stock traded hands. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $94.79. The firm has a 50-day moving average of $72.62 and a 200 day moving average of $73.86. The company’s market cap is $6.06 billion.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company’s revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.24) earnings per share. Equities analysts forecast that DexCom, Inc. will post ($0.78) EPS for the current year.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.